Parabilis Medicines (PBLS) holder reports 527,070-share Series F position

Rhea-AI Filing Summary

Parabilis Medicines, Inc. filed an initial ownership report showing that investment entities associated with Soleus Capital hold Series F Preferred Stock that is convertible into 527,070 shares of Common Stock at a conversion price of $9.48 per share. The securities are owned directly by Soleus Private Equity Fund III, L.P., with various Soleus general partner and management entities, and Guy Levy, identified as indirect 10% owners. The filing notes that the preferred stock is convertible at any time at the holder’s election and has no expiration date, and the reporting persons disclaim beneficial ownership beyond their pecuniary interests.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Levy Guy, Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC, Soleus Capital Management, L.P., Soleus GP, LLC

Role null | null | null | null | null | null

Type	Security	Shares	Price	Value
holding	Series F Preferred Stock	--	--	--

Holdings After Transaction: Series F Preferred Stock — 527,070 shares (Indirect, See footnote)

Footnotes (1)

1. The reportable securities are owned directly by Soleus Private Equity Fund III, L.P. ("Soleus PE"). Soleus Private Equity GP III, LLC ("Soleus PE GP") is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management, L.P. ("SCM") is the investment manager for Soleus PE, and Soleus GP, LLC ("Soleus GP") is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and Soleus GP. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP disclaims beneficial ownership of the securities held by Soleus PE other than for the purpose of determining their obligations under Section 16 of the Securities Exchange Act of 1934, as amended, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such securities for any other purpose, except to the extent of their respective pecuniary interests therein. The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

Key Figures

Underlying common shares: 527,070 shares Conversion price: $9.48 per share

2 metrics

Underlying common shares 527,070 shares Underlying Common Stock for Series F Preferred Stock holdings

Conversion price $9.48 per share Conversion price of Series F Preferred Stock into Common Stock

Key Terms

Series F Preferred Stock, convertible preferred stock, beneficial ownership, Section 16 of the Securities Exchange Act of 1934

4 terms

Series F Preferred Stock financial

"The reportable securities are owned directly by Soleus Private Equity Fund III, L.P."

Series F preferred stock is a class of company shares that gives holders priority over common shareholders for dividend payments and for getting money back if the company is sold or liquidated, much like a ticket that moves you to the front of the line. These shares often carry a fixed dividend and special rights—sometimes including conversion into common stock—so investors consider them when weighing income, downside protection and potential ownership dilution.

convertible preferred stock financial

"The convertible preferred stock is convertible at any time, at the holder's election"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

beneficial ownership financial

"disclaims beneficial ownership of the securities held by Soleus PE"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Section 16 of the Securities Exchange Act of 1934 regulatory

"for the purpose of determining their obligations under Section 16 of the Securities Exchange Act of 1934"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/29/2026 - 10:38 AM Accepted by SEC EDGAR 06/29/2026 - 10:38 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Levy Guy

(Last) (First) (Middle)

C/O SOLEUS CAPITAL MANAGEMENT, L.P.

100 FIELD POINT ROAD, SUITE 200

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series F Preferred Stock	(2)	(2)	Common Stock	527,070	$9.48	I	See footnote(1)

1. Name and Address of Reporting Person^*

Levy Guy

(Last) (First) (Middle)

C/O SOLEUS CAPITAL MANAGEMENT, L.P.

100 FIELD POINT ROAD, SUITE 200

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Soleus Private Equity Fund III, L.P.

(Last) (First) (Middle)

100 FIELD POINT ROAD, SUITE 200

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Soleus Private Equity GP III, LLC

(Last) (First) (Middle)

100 FIELD POINT ROAD, SUITE 200

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Soleus PE GP III, LLC

(Last) (First) (Middle)

100 FIELD POINT ROAD, SUITE 200

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Soleus Capital Management, L.P.

(Last) (First) (Middle)

100 FIELD POINT ROAD, SUITE 200

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Soleus GP, LLC

(Last) (First) (Middle)

100 FIELD POINT ROAD, SUITE 200

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The reportable securities are owned directly by Soleus Private Equity Fund III, L.P. ("Soleus PE"). Soleus Private Equity GP III, LLC ("Soleus PE GP") is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management, L.P. ("SCM") is the investment manager for Soleus PE, and Soleus GP, LLC ("Soleus GP") is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and Soleus GP. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP disclaims beneficial ownership of the securities held by Soleus PE other than for the purpose of determining their obligations under Section 16 of the Securities Exchange Act of 1934, as amended, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such securities for any other purpose, except to the extent of their respective pecuniary interests therein.

2. The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

	Guy Levy /s/ Guy Levy	06/29/2026
	Soleus Private Equity Fund III, L.P., /s/ Guy Levy, Managing Member of Soleus PE GP III, LLC, which is the Manager of Soleus Private Equity GP III, LLC, which is the General Partner of Soleus Private Equity Fund III, L.P.	06/29/2026
	Soleus Private Equity GP III, LLC /s/ Guy Levy, Managing Member of Soleus PE GP III, LLC, which is the Manager of Soleus Private Equity GP III, LLC	06/29/2026
	Soleus PE GP III, LLC /s/ Guy Levy, Managing Member	06/29/2026
	Soleus Capital Management, L.P., /s/ Guy Levy, the Managing Member of the General Partner of Soleus Capital Management, L.P.	06/29/2026
	Soleus GP, LLC, /s/ Guy Levy, Managing Member	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Parabilis Medicines (PBLS) Form 3 filing disclose?

The Form 3 discloses initial ownership of convertible preferred stock. Entities associated with Soleus Capital report holdings of Series F Preferred Stock in Parabilis Medicines, convertible into 527,070 common shares at $9.48 per share, establishing them as significant, over-10% beneficial owners.

How many Parabilis Medicines (PBLS) shares are tied to the reported preferred stock?

The reported Series F Preferred Stock is convertible into 527,070 common shares. The filing states this underlying amount of Common Stock, giving investors a clear view of the equity exposure represented by the Soleus Private Equity Fund III, L.P. position.

Who actually owns the Parabilis Medicines (PBLS) securities reported in this Form 3?

The securities are owned directly by Soleus Private Equity Fund III, L.P. Related Soleus entities and Guy Levy are listed as indirect 10% owners. The filing explains that these parties disclaim beneficial ownership except to the extent of their respective pecuniary interests.

What are the conversion terms of the Parabilis Medicines (PBLS) Series F Preferred Stock?

The convertible preferred stock can be converted at any time by the holder. The filing notes that the Series F Preferred Stock has no expiration date and is convertible into Common Stock at a conversion price of $9.48 per share, at the holder’s election.

Why is Guy Levy listed on the Parabilis Medicines (PBLS) Form 3?

Guy Levy is identified as the managing member of key Soleus entities. The filing explains his control roles in Soleus general partner and management entities but states he disclaims beneficial ownership of Soleus PE’s securities, except for his pecuniary interest under Section 16 rules.

Does the Parabilis Medicines (PBLS) Form 3 show any recent buy or sell transactions?

The Form 3 functions as an initial ownership statement, not a trade report. It presents holdings of Series F Preferred Stock and the related 527,070 underlying common shares, rather than documenting new purchases or sales of Parabilis Medicines securities.